JP2017530099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530099A5 JP2017530099A5 JP2017510495A JP2017510495A JP2017530099A5 JP 2017530099 A5 JP2017530099 A5 JP 2017530099A5 JP 2017510495 A JP2017510495 A JP 2017510495A JP 2017510495 A JP2017510495 A JP 2017510495A JP 2017530099 A5 JP2017530099 A5 JP 2017530099A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- fzd
- signaling agonist
- signaling
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011664 signaling Effects 0.000 claims description 77
- 239000000556 agonist Substances 0.000 claims description 62
- 108050003627 Wnt Proteins 0.000 claims description 51
- 102000013814 Wnt Human genes 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 102000015735 Beta-catenin Human genes 0.000 claims description 10
- 108060000903 Beta-catenin Proteins 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 101710181403 Frizzled Proteins 0.000 claims description 6
- 102000005698 Frizzled receptors Human genes 0.000 claims description 6
- 108010045438 Frizzled receptors Proteins 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000008960 Diabetic foot Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 102000023732 binding proteins Human genes 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims description 2
- 101100394745 Bacillus subtilis (strain 168) hepT gene Proteins 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 201000010927 Mucositis Diseases 0.000 claims description 2
- 101100338762 Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / CIP 104194 / JCM 7457 / NBRC 12017 / NCIMB 9290 / NRRL B-14731 / HIM 762-3) hepB gene Proteins 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 2
- 206010040844 Skin exfoliation Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 230000006727 cell loss Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 210000003027 ear inner Anatomy 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 102000050762 human DKK1 Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 210000001503 joint Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 210000005084 renal tissue Anatomy 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 102000016362 Catenins Human genes 0.000 claims 1
- 108010067316 Catenins Proteins 0.000 claims 1
- 102000007982 Phosphoproteins Human genes 0.000 claims 1
- 108010089430 Phosphoproteins Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000002220 organoid Anatomy 0.000 claims 1
- 210000003370 receptor cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 2
- 102100025036 Norrin Human genes 0.000 description 1
- 101710085992 Norrin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049949P | 2014-09-12 | 2014-09-12 | |
| US62/049,949 | 2014-09-12 | ||
| US201562206150P | 2015-08-17 | 2015-08-17 | |
| US62/206,150 | 2015-08-17 | ||
| PCT/US2015/049829 WO2016040895A1 (en) | 2014-09-12 | 2015-09-11 | Wnt signaling agonist molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138446A Division JP2020186267A (ja) | 2014-09-12 | 2020-08-19 | Ｗｎｔシグナリングアゴニスト分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530099A JP2017530099A (ja) | 2017-10-12 |
| JP2017530099A5 true JP2017530099A5 (enExample) | 2018-09-13 |
| JP6796059B2 JP6796059B2 (ja) | 2020-12-02 |
Family
ID=55459641
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510495A Active JP6796059B2 (ja) | 2014-09-12 | 2015-09-11 | Ｗｎｔシグナリングアゴニスト分子 |
| JP2020138446A Withdrawn JP2020186267A (ja) | 2014-09-12 | 2020-08-19 | Ｗｎｔシグナリングアゴニスト分子 |
| JP2023080152A Pending JP2023091081A (ja) | 2014-09-12 | 2023-05-15 | Ｗｎｔシグナリングアゴニスト分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138446A Withdrawn JP2020186267A (ja) | 2014-09-12 | 2020-08-19 | Ｗｎｔシグナリングアゴニスト分子 |
| JP2023080152A Pending JP2023091081A (ja) | 2014-09-12 | 2023-05-15 | Ｗｎｔシグナリングアゴニスト分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US11142577B2 (enExample) |
| EP (2) | EP4219564A1 (enExample) |
| JP (3) | JP6796059B2 (enExample) |
| AU (2) | AU2015314771B2 (enExample) |
| CA (1) | CA2959045A1 (enExample) |
| WO (1) | WO2016040895A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2959045A1 (en) | 2014-09-12 | 2016-03-17 | The University Of Washington | Wnt signaling agonist molecules |
| US20170349659A1 (en) * | 2016-06-03 | 2017-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt signaling agonist molecules |
| JP7617603B2 (ja) | 2017-01-11 | 2025-01-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子 |
| CA3050133A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| KR101966523B1 (ko) * | 2017-05-29 | 2019-04-05 | 차의과학대학교 산학협력단 | 오가노이드 배양을 위한 조성물 및 방법 |
| EP3731867A4 (en) * | 2017-12-19 | 2022-04-06 | Surrozen Operating, Inc. | Anti-lrp5/6 antibodies and methods of use |
| US11773171B2 (en) * | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| EP3728323A4 (en) * | 2017-12-19 | 2022-01-26 | Surrozen Operating, Inc. | ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE |
| SG11202007675VA (en) * | 2018-02-14 | 2020-09-29 | Antlera Therapeutics Inc | Multivalent binding molecules activating wnt signaling and uses thereof |
| CN111868078A (zh) | 2018-03-16 | 2020-10-30 | 斯坦福大学托管董事会 | 使用wnt激动剂和生物活性脂质用于生成和扩增心肌细胞的试剂和方法 |
| DK3820906T3 (da) * | 2018-07-05 | 2025-12-15 | Surrozen Operating Inc | Multispecifikke wnt-surrogatmolekyler og anvendelser deraf |
| EP3820499A4 (en) | 2018-07-09 | 2022-07-13 | Surrozen Operating, Inc. | TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES |
| US12084684B2 (en) | 2018-07-16 | 2024-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Frizzled specific Wnt agonists and antagonists |
| WO2020132356A1 (en) * | 2018-12-19 | 2020-06-25 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| EP3924381A4 (en) * | 2019-02-11 | 2023-07-26 | Surrozen Operating, Inc. | MODULATION OF WNT SIGNALING IN EYE DISEASES |
| CN113613717A (zh) * | 2019-03-11 | 2021-11-05 | 瑟罗泽恩公司 | 调节胃肠道病症中的wnt信号传导 |
| CN114423784B (zh) * | 2019-06-11 | 2025-01-03 | 安托拉诊疗公司 | 多价fzd和wnt结合分子及其用途 |
| EP3789049A1 (en) | 2019-09-06 | 2021-03-10 | QGel SA | Method for obtaining healthy intestinal organoids |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| AU2022232380A1 (en) * | 2021-03-10 | 2023-09-21 | Surrozen Operating, Inc. | Modulation of wnt signaling in gastrointestinal disorders |
| CA3240866A1 (en) * | 2021-12-17 | 2023-06-22 | Surrozen Operating, Inc. | Wnt-surrogate agents and methods for lacrimal gland regeneration |
| WO2024227103A1 (en) * | 2023-04-27 | 2024-10-31 | Surrozen Operating, Inc. | Molecules modulating wnt signaling pathways and uses thereof |
| WO2024249444A2 (en) * | 2023-05-29 | 2024-12-05 | Surrozen Operating, Inc. | Wnt surrogate agents and methods for lacrimal gland regeneration |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| DK0604552T3 (da) | 1991-09-18 | 1997-08-04 | Affymax Tech Nv | Fremgangsmåde til syntese af forskellige samlinger af oligomerer |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69333087T2 (de) | 1992-10-01 | 2004-05-06 | The Trustees Of Columbia University In The City Of New York | Komplexe kombinatorische chemische banken, die mit markierungen versehen sind |
| EP0726906A4 (en) | 1993-11-02 | 1998-10-07 | Affymax Tech Nv | THE SYNTHESIS AND EXAMINATION OF MOLECULAR DIVERSITY |
| CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
| US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| WO2001074164A1 (en) | 2000-03-31 | 2001-10-11 | The General Hospital Corporation | Methods of modulating hair growth |
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8343922B2 (en) | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| EP1786837B1 (en) | 2004-08-04 | 2013-05-01 | Amgen Inc., | Antibodies to dkk-1 |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| JP2008542366A (ja) | 2005-05-30 | 2008-11-27 | アストラゼネカ・アクチエボラーグ | Ｆｚｄ８モジュレーターを同定する方法および変形性関節症を処置するためのそのようなモジュレーターの使用 |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| BRPI0707514A2 (pt) * | 2006-02-07 | 2011-05-10 | Wyeth Corp | mÉtodo de identificaÇço de um agente que module ossos ou um lipÍdio; mÉtodo de identificaÇço de um agente que module a atividade de norrin-frizzled4; kit para identificar um agente que module a atividade de lrp5-norrin-frizzled4; cÉlula ou linhagem celular desprovida de norrin nativo e que expresse uma lrp5 nço nativa e uma frizzled4 nço nativa |
| AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| CN101573383B (zh) | 2006-06-21 | 2015-05-13 | 肿瘤疗法科学股份有限公司 | 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途 |
| US20100199362A1 (en) | 2007-04-26 | 2010-08-05 | President And Fellows Of Harvard College | Wnt ligands involved in blood-brain barrier development and uses therefor |
| KR20100091170A (ko) | 2007-11-02 | 2010-08-18 | 노파르티스 아게 | 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법 |
| CA2705923A1 (en) | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Antibodies to lrp6 |
| WO2010016766A2 (en) | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| WO2010030813A2 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
| SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| PL2393917T3 (pl) | 2009-02-03 | 2016-12-30 | Podłoże do hodowli nabłonkowych komórek macierzystych i organoidów zawierających komórki macierzyste | |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| AU2011217964B2 (en) | 2010-02-19 | 2016-07-14 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof |
| JP6093692B2 (ja) | 2010-03-24 | 2017-03-08 | ジェネンテック， インコーポレイテッド | 抗ｌｒｐ６抗体 |
| NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| CA2798432A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| SG185415A1 (en) * | 2010-05-06 | 2012-12-28 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| BR112013019280A2 (pt) * | 2011-01-28 | 2017-03-21 | Univ Leland Stanford Junior | composições wnt e métodos para sua utilização |
| GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| EP3252075A1 (en) | 2011-11-04 | 2017-12-06 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
| DK2794658T3 (en) | 2011-12-19 | 2017-06-19 | Synimmune Gmbh | BISPECIFIC ANTIBODY MOLECULE |
| CN104066449B (zh) | 2012-01-18 | 2018-04-27 | 霍夫曼-拉罗奇有限公司 | 抗lrp5抗体及使用方法 |
| EP2888279A1 (en) | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anti lrp6 antibodies |
| WO2014059068A1 (en) | 2012-10-11 | 2014-04-17 | The Trustees Of The University Of Pennsylvania | Methods for the treatment and prevention of osteoporosis and bone-related disorders |
| HK1211887A1 (en) | 2013-02-04 | 2016-06-03 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
| CA2900764A1 (en) | 2013-02-08 | 2014-08-14 | Stemcentrx, Inc. | Novel multispecific constructs |
| CN105431161A (zh) * | 2013-02-21 | 2016-03-23 | 范安德尔研究所 | Norrin突变体多肽、其制造方法和用途 |
| MX2015011518A (es) | 2013-03-14 | 2016-02-03 | Oncomed Pharm Inc | Agentes de enlace de met y usos de los mismos. |
| GB2518221A (en) | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| CA2959045A1 (en) | 2014-09-12 | 2016-03-17 | The University Of Washington | Wnt signaling agonist molecules |
| US9777052B2 (en) | 2014-12-02 | 2017-10-03 | The Board Of Regents Of The University Of Oklahoma | R-spondin variants, compositions, and methods of use |
| US20160312207A1 (en) | 2015-04-21 | 2016-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling |
-
2015
- 2015-09-11 CA CA2959045A patent/CA2959045A1/en active Pending
- 2015-09-11 AU AU2015314771A patent/AU2015314771B2/en active Active
- 2015-09-11 US US15/508,779 patent/US11142577B2/en active Active
- 2015-09-11 EP EP23157332.0A patent/EP4219564A1/en not_active Withdrawn
- 2015-09-11 JP JP2017510495A patent/JP6796059B2/ja active Active
- 2015-09-11 WO PCT/US2015/049829 patent/WO2016040895A1/en not_active Ceased
- 2015-09-11 EP EP15840226.3A patent/EP3191526B1/en active Active
-
2020
- 2020-08-19 JP JP2020138446A patent/JP2020186267A/ja not_active Withdrawn
-
2021
- 2021-05-13 AU AU2021203059A patent/AU2021203059A1/en not_active Abandoned
- 2021-09-08 US US17/469,661 patent/US20210403578A1/en not_active Abandoned
-
2023
- 2023-05-15 JP JP2023080152A patent/JP2023091081A/ja active Pending
-
2024
- 2024-04-04 US US18/627,108 patent/US20250011437A1/en not_active Abandoned
-
2025
- 2025-03-03 US US19/069,060 patent/US20250304702A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530099A5 (enExample) | ||
| CL2024002249A1 (es) | Muteína de il-21; conjugado; método de producción; composición farmacéutica; y su uso. | |
| Chan et al. | Matrix‐bound vegf mimetic peptides: design and endothelial‐cell activation in collagen scaffolds | |
| ES2585702T3 (es) | Composiciones y métodos para la unión al ácido lisofosfatídico | |
| Wilson et al. | Stoichiometric post‐modification of hydrogel microparticles dictates neural stem cell fate in microporous annealed particle scaffolds | |
| MX2021014601A (es) | Proteinas recombinantes de union a fap y su uso. | |
| JP2012511545A5 (enExample) | ||
| BR112012028326A2 (pt) | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos | |
| DK2343320T3 (da) | Anti-gitr-antistoffer og anvendelser deraf | |
| JP2017000143A5 (enExample) | ||
| DE602005019064D1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| CY1118389T1 (el) | Νεα αντισωματα ανταγωνιστων και fab θραυσματα αυτων εναντι του gpvi και χρησεις αυτων | |
| JP2017507670A5 (enExample) | ||
| JP2016509011A5 (enExample) | ||
| WO2011036445A3 (en) | Polypeptides and uses thereof | |
| ATE485517T1 (de) | Verfahren zur identifizierung von polypeptid- targets | |
| RU2018108421A (ru) | Рекомбинантные белки и их применения в терапевтических целях | |
| MX2023010365A (es) | Proteina liofilizada estable a temperatura ambiente. | |
| JP2014510519A5 (enExample) | ||
| NZ749578A (en) | Anti-met antibodies and uses thereof | |
| JP2010501594A5 (enExample) | ||
| Rao et al. | Tenogenic induction of human adipose-derived stem cells by soluble tendon extracellular matrix: Composition and transcriptomic analyses | |
| JP2018512124A5 (enExample) | ||
| BRPI0607883A2 (pt) | método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular | |
| ME02491B (me) | Proteini koji vezuju antigene specifični za serumsku amiloidnu p komponentu |